124 related articles for article (PubMed ID: 2257224)
1. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells.
Scambia G; Ranelletti FO; Panici PB; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Rumi C; Larocca LM; Mancuso S
Br J Cancer; 1990 Dec; 62(6):942-6. PubMed ID: 2257224
[TBL] [Abstract][Full Text] [Related]
2. Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; Rumi C; Battaglia F; Larocca LM; Capelli A; Mancuso S
Int J Cancer; 1990 Dec; 46(6):1112-6. PubMed ID: 2249899
[TBL] [Abstract][Full Text] [Related]
3. Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids.
Larocca LM; Piantelli M; Leone G; Sica S; Teofili L; Panici PB; Scambia G; Mancuso S; Capelli A; Ranelletti FO
Br J Haematol; 1990 Aug; 75(4):489-95. PubMed ID: 2207000
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth.
Scambia G; Ranelletti FO; Benedetti Panici P; Bonanno G; De Vincenzo R; Piantelli M; Mancuso S
Anticancer Drugs; 1990 Oct; 1(1):45-8. PubMed ID: 2131036
[TBL] [Abstract][Full Text] [Related]
5. Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors.
Ranelletti FO; Ricci R; Larocca LM; Maggiano N; Capelli A; Scambia G; Benedetti-Panici P; Mancuso S; Rumi C; Piantelli M
Int J Cancer; 1992 Feb; 50(3):486-92. PubMed ID: 1735617
[TBL] [Abstract][Full Text] [Related]
6. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; Bonanno G; De Vincenzo R; Ferrandina G; Pierelli L; Capelli A; Mancuso S
Cancer Chemother Pharmacol; 1991; 28(4):255-8. PubMed ID: 1879042
[TBL] [Abstract][Full Text] [Related]
7. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer.
Caltagirone S; Ranelletti FO; Rinelli A; Maggiano N; Colasante A; Musiani P; Aiello FB; Piantelli M
Am J Respir Cell Mol Biol; 1997 Jul; 17(1):51-9. PubMed ID: 9224209
[TBL] [Abstract][Full Text] [Related]
8. Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines.
Scambia G; Ranelletti FO; Panici PB; Piantelli M; De Vincenzo R; Ferrandina G; Bonanno G; Capelli A; Mancuso S
Int J Cancer; 1993 May; 54(3):462-6. PubMed ID: 8509221
[TBL] [Abstract][Full Text] [Related]
9. Growth-inhibitory effect of tamoxifen and quercetin and presence of type II estrogen binding sites in human laryngeal cancer cell lines and primary laryngeal tumors.
Ferrandina G; Almadori G; Maggiano N; Lanza P; Ferlini C; Cattani P; Piantelli M; Scambia G; Ranelletti FO
Int J Cancer; 1998 Aug; 77(5):747-54. PubMed ID: 9688309
[TBL] [Abstract][Full Text] [Related]
10. Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas.
Piantelli M; Rinelli A; Macrì E; Maggiano N; Larocca LM; Scerrati M; Roselli R; Iacoangeli M; Scambia G; Capelli A
Cancer; 1993 Jan; 71(1):193-8. PubMed ID: 8416715
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression?
Lama G; Angelucci C; Bruzzese N; Iacopino F; Nori SL; D'Atri S; Turriziani M; Bonmassar E; Sica G
Melanoma Res; 1998 Aug; 8(4):313-22. PubMed ID: 9764806
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin.
Scambia G; De Vincenzo R; Ranelletti FO; Panici PB; Ferrandina G; D'Agostino G; Fattorossi A; Bombardelli E; Mancuso S
Eur J Cancer; 1996 May; 32A(5):877-82. PubMed ID: 9081370
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory effect of quercetin and presence of type II estrogen binding sites in primary human transitional cell carcinomas.
Larocca LM; Giustacchini M; Maggiano N; Ranelletti FO; Piantelli M; Alcini E; Capelli A
J Urol; 1994 Sep; 152(3):1029-33. PubMed ID: 8051728
[TBL] [Abstract][Full Text] [Related]
14. Quercetin enhances transforming growth factor beta 1 secretion by human ovarian cancer cells.
Scambia G; Panici PB; Ranelletti FO; Ferrandina G; De Vincenzo R; Piantelli M; Masciullo V; Bonanno G; Isola G; Mancuso S
Int J Cancer; 1994 Apr; 57(2):211-5. PubMed ID: 8157359
[TBL] [Abstract][Full Text] [Related]
15. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth.
Teofili L; Pierelli L; Iovino MS; Leone G; Scambia G; De Vincenzo R; Benedetti-Panici P; Menichella G; Macrì E; Piantelli M
Leuk Res; 1992; 16(5):497-503. PubMed ID: 1625476
[TBL] [Abstract][Full Text] [Related]
16. Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships.
De Vincenzo R; Scambia G; Benedetti Panici P; Ranelletti FO; Bonanno G; Ercoli A; Delle Monache F; Ferrari F; Piantelli M; Mancuso S
Anticancer Drug Des; 1995 Sep; 10(6):481-90. PubMed ID: 7575989
[TBL] [Abstract][Full Text] [Related]
17. Quercetin and hyperthermia produce a synergistic inhibitory effect on primary human ovarian-cancer cells.
Scambia G; Ranelletti F; Panici P; Devincenzo R; Bonanno G; Ferrandina G; Piantelli M; Mancuso S
Int J Oncol; 1992 Aug; 1(3):299-302. PubMed ID: 21584546
[TBL] [Abstract][Full Text] [Related]
18. Interaction of tamoxifen with cytosolic and nuclear type II estrogen binding sites (type II EBS).
Ferrandina G; Ranelletti FO; Scambia G; Benedetti Panici P; D'Agostino G; Piantelli M; Isola G; Mancuso S
Cancer Lett; 1995 Sep; 96(1):123-31. PubMed ID: 7553600
[TBL] [Abstract][Full Text] [Related]
19. Type II estrogen-binding sites in human ovarian cancer: correlation with estrogen, progesterone, and epidermal growth factor receptor.
Ferrandina G; Scambia G; Benedetti Panici P; Ranelletti FO; De Vincenzo R; Piantelli M; Distefano M; Capelli A; Mancuso S
Gynecol Oncol; 1993 Apr; 49(1):67-72. PubMed ID: 8482562
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells.
Piantelli M; Maggiano N; Ricci R; Larocca LM; Capelli A; Scambia G; Isola G; Natali PG; Ranelletti FO
J Invest Dermatol; 1995 Aug; 105(2):248-53. PubMed ID: 7636308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
